Which has the lower trailing P/E, ALNY or RMD?

RMD has the lower trailing P/E: ALNY trades at 37.22 and RMD at 20.40. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ALNY or RMD?

Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus RMD at 12.37%.

Does ALNY or RMD pay a bigger dividend?

RMD pays a dividend (1.14% yield), while ALNY has no payments in the available dividend history.

Is ALNY or RMD more profitable?

RMD runs the higher net margin — ALNY at 16.82% versus RMD at 27.44%.

How have ALNY and RMD total returns compared?

Over the past 10 years, ALNY delivered 11.94% and RMD delivered 13.11% annualized total return. Past performance doesn't predict future results.

Alnylam Pharmaceuticals, Inc. (ALNY) vs ResMed Inc. (RMD)

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and ResMed Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 4, 2026. Differences are shown without an overall score or investment verdict.

ALNY

Alnylam Pharmaceuticals, Inc.

$29.48B

$220.33HealthcareDelayed quote: Aug 3, 2026, 4:00 PM EDT

RMD

ResMed Inc.

$31.21B

$215.19HealthcareDelayed quote: Aug 3, 2026, 4:00 PM EDT

Total return — ALNY vs RMD

growth of $100 · dividends reinvested · last 22y

ALNY +4698.8%RMD +1984.1%ALNY compounded faster

ALNY RMD

ALNY vs RMD: by the numbers

•RMD is the larger company ($31.21B vs $29.48B market cap).
•RMD trades at the lower trailing earnings multiple (20.40 vs 37.22 P/E), one valuation lens rather than an overall verdict.
•RMD converts more revenue to profit (27.44% vs 16.82% net margin).
•ALNY grew revenue faster over the past five years (47.53% vs 12.37% CAGR).
•RMD pays a dividend (1.14% yield), while ALNY has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	ALNY	RMD
P/E ratio	37.22	20.40
Forward P/E	32.58	18.96
P/S ratio	6.34	5.60
P/B ratio	22.49	4.78
PEG ratio	N/A	0.72
EV / EBITDA	28.48	14.04
FCF yield	1.78%	5.64%

Profitability

Metric	ALNY	RMD
Gross margin	79.72%	61.69%
Operating margin	20.81%	34.28%
Net margin	16.82%	27.44%
ROE	59.67%	23.41%
ROIC	13.74%	19.56%

Dividends

Metric	ALNY	RMD
Dividend yield	N/A	1.14%
Payout ratio	N/A	25.13%

Growth (annualized)

Metric	ALNY	RMD
Revenue CAGR (5Y)	47.53%	12.37%
EPS CAGR (5Y)	N/A	17.25%
FCF CAGR (5Y)	N/A	18.98%
Total return CAGR (5Y)	4.27%	-4.09%

Frequently asked

Which has the lower trailing P/E, ALNY or RMD?: RMD has the lower trailing P/E: ALNY trades at 37.22 and RMD at 20.40. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ALNY or RMD?: Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus RMD at 12.37%.
Does ALNY or RMD pay a bigger dividend?: RMD pays a dividend (1.14% yield), while ALNY has no payments in the available dividend history.
Is ALNY or RMD more profitable?: RMD runs the higher net margin — ALNY at 16.82% versus RMD at 27.44%.
How have ALNY and RMD total returns compared?: Over the past 10 years, ALNY delivered 11.94% and RMD delivered 13.11% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALNY analysis Full RMD analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio ResMed P/E ratio Alnylam Pharmaceuticals dividend yield ResMed dividend yield Alnylam Pharmaceuticals ROE ResMed ROE Alnylam Pharmaceuticals operating margin ResMed operating margin Alnylam Pharmaceuticals revenue growth ResMed revenue growth Alnylam Pharmaceuticals free cash flow ResMed free cash flow

Alnylam Pharmaceuticals & ResMed appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 4, 2026.